Creative biotech for Alzheimer’s and beyond.
S2N’s vision is a world where neuronal loss no longer means loss. Our regenerative medicine technology starts with the human hair follicle and ends with millions of pure neurons, all gene modification free. Our purpose is to transform health, science and society.
S2N Science
Therapeutics
Basic Science
S2N’s lead therapeutic target is Alzheimer’s dementia. Our technology also has potential to treat neurodegenerative conditions such as Parkinson’s disease, Huntington’s disease and more.
S2N Core Technology
Our journey began with discovery of Hair Follicle-derived Neuroprecursor (HFN) cells by S2N co-founder and CEO, Professor Michael Valenzuela and team. These cells are 100% natural, originating from the hair follicle of human skin and are unipotent - meaning they have the remarkable ability to only become neurons (brain cells).
In a pioneering series of studies spanning 15 years, Professor Valenzuela and collaborators showed these types of cells can engraft and integrate into the memory circuits of different animals. And in a peer reviewed world-first veterinary trial, the team found this type of cell could reverse an Alzheimer dementia syndrome in doggie patients, completely transforming their quality of life!
S2N was therefore created to transform this science into a powerful new class of neurorestorative medicine. Our proprietary manufacturing processes allows us to isolate, purify and expand the rare HFNs in a person’s skin, producing a personalized batch of cells. Critically, our unique technology allows us to do this time-and-time again in a reliable and efficient manner.
S2N is therefore on the cusp of human trial powered by a crystal-clear mission: to return meaning and dignity to people’s lives.
-
[News 06.22] S2N Reverses Dementia in Dogs
S2N has achieved what no one else has to date – reversal of a dementia-like syndrome in a natural animal form of Alzheimer’s disease.
-
[News 04.24] S2N awarded $2M by NSW Office of Chief Scientist
After a 1-year exhaustive evaluation of more than 80 biotech contenders, the New South Wales Office of the Chief Scientist and Engineer chose S2N for a $2M commercialisation award.
-
[News 04.24] S2N featured on Channel 7 News
Channel 7 news features S2N’s pioneering approach to treating Alzheimer’s in dogs.
S2N science is founded on the remarkable overlap between stem cell regulation in the brain and in human skin.
Learn more about basic stem cell biology in the skin.
Scientific Co-Founder Prof Michael Valenzuela showcased S2N’s approach to developing potency assays for our autologous cell therapy at the Sartorius-Select Science virtual industry summit [January 2022].
